dr. A.F. (Floriaan) Schmidt

dr. A.F. (Floriaan) Schmidt

Associate Professor
dr. A.F. (Floriaan) Schmidt
  • Department of Cardiology



A. Floriaan Schmidt has received training in public health, clinical epidemiology, and mathematics. Floriaan completed a PhD on methods for personalized medicine with the Utrecht University in the Netherlands. Following his PhD, he accepted a position with University College London (UCL). Currently, Floriaan has a joined position with UMC Utrecht and UCL. His research focusses on developing and applying human genetics for drug target validation (Schmidt, Nature Communications 2020 & 2021). Additionally, Floriaan conducts research to improve risk prediction modelling for patient subgroups by integrating electronic healthcare records data with information from multi-model sources including genomics and metabolomics. Floriaan has received funding from the British Heart Foundation, the National Institute for Health Research University College London Hospitals Biomedical Research Centre, Servier, IMI, and Erasmus+.

Side Activities

  1. Senior research fellow with the institute of cardiovascular science at University College London,
  2. Associate editor with Frontiers in Epidemiology. 

Fellowship and Awards


  • IMI BigData@Heart internal grant. Machine learning for Genetically guided drug discovery. For 96,150 euro.
  • IMI BigData@Heart internal grant. Describing and evaluating treatment and disease trajectories in cardiovascular disease. For 96,150 euro.
  • Erasmus+ dataclinic project to develop a European machine learning and engineering curriculum for healthcare professionals. For 400,000 euro.
  • Servier grant on Integrative bioinformatics for drug target validation. For 70,000 euro.
  • NIHR UCLH BRC grant on Developing approaches to personalised medicine in cardiovascular disease, a feasibility study. For 75,000 pound.
  • NIHR UCLH BRC grant on Translating -omics data for precision drug-development and re-purposing. For 50,000 pound.
  • NWO MyDigiTwin: Using Big-Data to put a cardiovascular digital twin into the hands of people. For 500,000 euro.
  • Network development grant, UMC Utrecht. For 16,000 euro.
  • Project Grant, British Heart Foundation on Evaluating combination therapeutics for CVD prevention using Mendelian randomization and phenome-wide scans. For 255,000 pound.
  • Springboard Population Science Fellowship on Genetically guided drug development methodologies. UCL excellence fellowship for 100,000 pound. 



  • 2022 European Atherosclerosis Society Young Investigator Award for outstanding publication.
  • 2017 Shortlisted for the London Cardiovascular Society Young Investigator Award.
  • 2017,2016 (2x) Pharmacoepidemiology and Drug Safety: best reviewer.
  • 2015 Journal of Clinical Epidemiology: reviewer of the year.
  • 2014 Royal College of Veterinary Surgeons: knowledge award bursary.
  • 2012 The Dutch epidemiology association: prize for best oral presentation.

Research Output (51)

Individualized Family Screening for Arrhythmogenic Right Ventricular Cardiomyopathy

Muller Steven A, Gasperetti Alessio, Bosman Laurens P, Schmidt Amand F, Baas Annette F, Amin Ahmad S, Houweling Arjan C, Wilde Arthur A M, Compagnucci Paolo, Targetti Mattia, Casella Michela, Calò Leonardo, Tondo Claudio, van der Harst Pim, Asselbergs Folkert W, van Tintelen J Peter, Oerlemans Marish I F J, Te Riele Anneline S J M 18 Jul 2023, In: Journal of the American College of Cardiology. 82 , p. 214-225 12 p.

Druggable proteins influencing cardiac structure and function:Implications for heart failure therapies and cancer cardiotoxicity

Schmidt Amand F, Bourfiss Mimount, Alasiri Abdulrahman, Puyol-Anton Esther, Chopade Sandesh, van Vugt Marion, van der Laan Sander W, Gross Christian, Clarkson Chris, Henry Albert, Lumbers Tom R, van der Harst Pim, Franceschini Nora, Bis Joshua C, Velthuis Birgitta K, Te Riele Anneline S J M, Hingorani Aroon D, Ruijsink Bram, Asselbergs Folkert W, van Setten Jessica, Finan Chris 28 Apr 2023, In: Science advances. 9 17 p.

Sex-specific Mendelian randomisation to assess the causality of sex differences in the effects of risk factors and treatment:spotlight on hypertension

de Ruiter Sophie C, Schmidt A Floriaan, Grobbee Diederick E, den Ruijter Hester M, Peters Sanne A E 7 Apr 2023, In: Journal of human hypertension. 37 , p. 602-608 7 p.

Untargeted Metabolomics Identifies Potential Hypertrophic Cardiomyopathy Biomarkers in Carriers of MYBPC3 Founder Variants

Jansen Mark, Schuldt Maike, van Driel Beau O, Schmidt Amand F, Christiaans Imke, van der Crabben Saskia N, Hoedemaekers Yvonne M, Dooijes Dennis, Jongbloed Jan D H, Boven Ludolf G, Deprez Ronald H Lekanne, Wilde Arthur A M, Jans Judith J M, van der Velden Jolanda, de Boer Rudolf A, van Tintelen J Peter, Asselbergs Folkert W, Baas Annette F 17 Feb 2023, In: International journal of molecular sciences. 24

Prevalence and Disease Expression of Pathogenic and Likely Pathogenic Variants Associated with Inherited Cardiomyopathies in the General Population

Bourfiss Mimount, Van Vugt Marion, Alasiri Abdulrahman I., Ruijsink Bram, Van Setten Jessica, Schmidt A. Floriaan, Dooijes Dennis, Puyol-Antón Esther, Velthuis Birgitta K., Van Tintelen J. Peter, Te Riele Anneline S.J.M., Baas Annette F., Asselbergs Folkert W. 20 Oct 2022, In: Circulation. Genomic and precision medicine. 15

Pharmacogenomics decision support in the U-PGx project:Results and advice from clinical implementation across seven European countries

Blagec Kathrin, Swen Jesse J., Koopmann Rudolf, Cheung Ka Chun, Crommentuijn-Van Rhenen Mandy, Holsappel Inge, Konta Lidija, Ott Simon, Steinberger Daniela, Xu Hong, Cecchin Erika, Dolžan Vita, Dávila-Fajardo Cristina Lucía, Patrinos George P., Sunder-Plassmann Gere, Turner Richard M., Pirmohamed Munir, Guchelaar Henk Jan, Samwald Matthias, Antolinos-Perez M. J., Blagus T., Cambon-Thomsen A., Deneer V. H., Dupui M., Grandia L., Hanson A., Ingelman-Sundberg M., Jama W., Jonsson S., Just K., Karlsson M. O., Katsila T., Klen J., Kriek M., Lauschke V. M., Díaz-Villamarín Xando, Manson L. E.N., Mitropoulou C., Mlinsek G., Moreno-Aguilar R., Nijenhuis M., Nordling , Poplas Susic A., Rial-Sebbag E., Rollinson V., Sanchez-Ramos J. G., Schaeffeler E., Schmidt A., Schwab M. Jun 2022, In: PLoS ONE. 17

Unravelling the Difference Between Men and Women in Post-CABG Survival

Schmidt Amand F, Haitjema Saskia, Sartipy Ulrik, Holzmann Martin J, Malenka David J, Ross Cathy S, van Gilst Wiek, Rouleau Jean L, Meeder Annelijn M, Baker Robert A, Shiomi Hiroki, Kimura Takeshi, Tran Lavinia, Smith Julian A, Reid Christopher M, Asselbergs Folkert W, den Ruijter Hester M 13 Apr 2022, In: Frontiers in cardiovascular medicine. 9 , p. 1-7

Human Genomics and Drug Development

Schmidt Amand F., Hingorani Aroon D., Finan Chris 1 Feb 2022, In: Cold Spring Harbor perspectives in medicine. 12

Cochrane corner:PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

Carter John Paul, Hingorani Aroon D., Wilkins John, Schmidt Amand Floriaan 1 Jan 2022, In: Heart (British Cardiac Society). 108 , p. 14-15 2 p.

Assessment of practical applicability and clinical relevance of a commonly used LDL-C polygenic score in patients with severe hypercholesterolemia

Tromp Tycho R., Cupido Arjen J., Reeskamp Laurens F., Stroes Erik S.G., Hovingh G. Kees, Defesche Joep C., Schmidt Amand F., Zuurbier Linda Jan 2022, In: Atherosclerosis. 340 , p. 61-67 7 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not